Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Influenza pandemics: can we prepare for the unpredictable?

Kilbourne ED.

Viral Immunol. 2004;17(3):350-7. Review.

PMID:
15357901
2.

[Genome composition analysis of the reassortant influenza viruses used in seasonal and pandemic live attenuated influenza vaccine].

Kiseleva IV, Voeten JT, Teley LC, Larionova NV, Dubrovina IA, Berdygulova ZhA, Bazhenova EA, van den Bosch H, Heldens JG, Rudenko LG.

Mol Gen Mikrobiol Virusol. 2011;(4):29-36. Russian.

PMID:
22312898
4.

Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus.

Isakova-Sivak I, de Jonge J, Smolonogina T, Rekstin A, van Amerongen G, van Dijken H, Mouthaan J, Roholl P, Kuznetsova V, Doroshenko E, Tsvetnitsky V, Rudenko L.

PLoS One. 2014 Jul 24;9(7):e102339. doi: 10.1371/journal.pone.0102339. eCollection 2014.

5.

Evaluation of three live attenuated H2 pandemic influenza vaccine candidates in mice and ferrets.

Chen GL, Lamirande EW, Cheng X, Torres-Velez F, Orandle M, Jin H, Kemble G, Subbarao K.

J Virol. 2014 Mar;88(5):2867-76. doi: 10.1128/JVI.01829-13. Epub 2013 Dec 26.

6.

Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus.

Rudenko L, Isakova-Sivak I.

Expert Rev Vaccines. 2015 Mar;14(3):395-412. doi: 10.1586/14760584.2015.979159. Epub 2015 Jan 2. Review.

PMID:
25555687
7.

Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control.

Hilleman MR.

Vaccine. 2002 Aug 19;20(25-26):3068-87. Review.

PMID:
12163258
8.

Influenza vaccines: a main problem in control of pandemics.

Ghendon Y.

Eur J Epidemiol. 1994 Aug;10(4):485-6.

PMID:
7843363
9.

Confronting the avian influenza threat: vaccine development for a potential pandemic.

Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM.

Lancet Infect Dis. 2004 Aug;4(8):499-509. Review.

PMID:
15288823
10.

Development of live attenuated influenza vaccines against pandemic influenza strains.

Coelingh KL, Luke CJ, Jin H, Talaat KR.

Expert Rev Vaccines. 2014 Jul;13(7):855-71. doi: 10.1586/14760584.2014.922417. Epub 2014 May 28. Review.

PMID:
24867587
11.

Production of pilot lots of inactivated influenza vaccine in response to a pandemic threat: an interim biosafety risk assessment.

[No authors listed]

Wkly Epidemiol Rec. 2003 Nov 21;78(47):405-8. English, French. No abstract available.

PMID:
14677515
12.

Vaccination against influenza: role and limitations in pandemic intervention plans.

Rebmann T, Zelicoff A.

Expert Rev Vaccines. 2012 Aug;11(8):1009-19. Review.

PMID:
23002981
13.

Generation and characterization of candidate vaccine viruses for prepandemic influenza vaccines.

O'Neill E, Donis RO.

Curr Top Microbiol Immunol. 2009;333:83-108. doi: 10.1007/978-3-540-92165-3_4. Review.

PMID:
19768401
14.

Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.

Jadhao SJ, Achenbach J, Swayne DE, Donis R, Cox N, Matsuoka Y.

Vaccine. 2008 Mar 25;26(14):1742-50. doi: 10.1016/j.vaccine.2008.01.036. Epub 2008 Feb 13.

PMID:
18336962
15.

High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1.

Zhou F, Zhou J, Ma L, Song S, Zhang X, Li W, Jiang S, Wang Y, Liao G.

Biochem Biophys Res Commun. 2012 May 18;421(4):850-4. doi: 10.1016/j.bbrc.2012.04.101. Epub 2012 Apr 25.

PMID:
22554519
16.

Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control.

Kreijtz JH, Osterhaus AD, Rimmelzwaan GF.

Hum Vaccin. 2009 Mar;5(3):126-35. Epub 2009 Mar 15. Review.

PMID:
18948744
17.

Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness.

Tseng YF, Hu AY, Huang ML, Yeh WZ, Weng TC, Chen YS, Chong P, Lee MS.

PLoS One. 2011;6(10):e24057. doi: 10.1371/journal.pone.0024057. Epub 2011 Oct 13.

18.

[Efficacy of production of reassortant of epidemic strains and cold-adapted influenza viruses in chicken embryo and MDCK cells].

Kiseleva IV, Isakova IN, Larionova NV, Oleń≠nik ES, Rudenko LG.

Zh Mikrobiol Epidemiol Immunobiol. 2007 Nov-Dec;(6):40-5. Russian.

PMID:
18283733
19.

Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.

Desheva JA, Lu XH, Rekstin AR, Rudenko LG, Swayne DE, Cox NJ, Katz JM, Klimov AI.

Vaccine. 2006 Nov 17;24(47-48):6859-66. Epub 2006 Jun 28.

PMID:
17050041
20.

Vaccines for pandemic influenza.

Luke CJ, Subbarao K.

Emerg Infect Dis. 2006 Jan;12(1):66-72. Review.

Supplemental Content

Support Center